Takeda UK announced today that all sales teams and support resource will be integrated into the company effective 1 st June 2016.
The field sales teams have been operated and managed by Ashfield Healthcare since 2004. This announcement impacts over 70 team members of the Oncology Key Account Manager (KAM) team, Inflammatory Bowel Disease (IBD) KAM team and the entire General Medicine Regional Account Director (RAD) and Customer Account Specialist (CAS) teams.
These team members will transition to become Takeda employees from 1st June, 2016 following the conclusion of a consultation and transition process in line with legislative requirements.
This move will nearly double the number of Takeda employees in the UK and is part of an ambitious growth strategy to become an agile, specialty care provider focused on specific opportunities in Oncology, IBD and Diabetes.
Adam Zaeske, Managing Director, Takeda UK & Ireland said: “Takeda and Ashfield Healthcare were pioneers when the RAD/KAM model was conceived in 2004. The partnership has been a tremendous success and is still recognised with many major companies adopting a similar approach.”
“Today Takeda is at the cusp of a significant growth phase with specific opportunities in Oncology, IBD and Diabetes. We have made the strategic decision to integrate our sales teams as we recognise the critical role they play in growing our business and continuing to build a strong organisation.”
“This is an incredibly exciting time for Takeda as we transform our business as an agile, specialty care provider. This announcement is about forging one integrated team and is the latest step in that journey.”
“I sincerely thank our partners at Ashfield Healthcare for their hard work and support over the years. This announcement is a validation of Ashfield’s ability to help build healthcare companies and propel them forward through expertise and ingenuity. Takeda UK is strong today in large measure because of our partnership with Ashfield Healthcare.”
Source: Takeda
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
